SCHEMBL1639802

SCHEMBL1639802

CC(C)(C)OC(=O)N1CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)C1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 17/20 0.66
TGFBR1 P36897 1/20 0.63
CSNK1D P48730 5/20 0.62
MAPK13 O15264 3/20 0.62
MAPK12 P53778 3/20 0.62
MAPK11 Q15759 3/20 0.62
PRKD3 O94806 3/20 0.62
MAP4K4 O95819 3/20 0.62
CSNK1A1 P48729 3/20 0.62
MINK1 Q8N4C8 3/20 0.62
MAP4K5 Q9Y4K4 3/20 0.62
LCK P06239 2/20 0.62
MAPK9 P45984 2/20 0.62
PRKD2 Q9BZL6 2/20 0.62
PRKACA P17612 2/20 0.62
RIPK2 O43353 1/20 0.62
DYRK3 O43781 1/20 0.62
PRKCG P05129 1/20 0.62
LYN P07948 1/20 0.62
RET P07949 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639781 0.93 MAPK14 (0.72) MAPK14TGFBR1CSNK1DMAPK13MAPK12
SCHEMBL27545277 0.91 MAPK14 (0.80) MAPK14TGFBR1CSNK1DMAPK13MAPK12
SCHEMBL1640978 0.86 MAPK14 (0.71) MAPK14CSNK1DMAPK13MAPK12MAPK11
Ammonia Solution, Strong SCHEMBL27870854 0.85 TGFBR1 (0.62) MAPK14TGFBR1CSNK1DMAPK13MAPK12
SCHEMBL7884407 0.83 MAPK14 (0.68) MAPK14TGFBR1CSNK1DMAPK13MAPK12
SCHEMBL15830596 0.81 TGFBR1 (0.69) TGFBR1CSNK1DCSNK1E
SCHEMBL1640716 0.81 MAPK14 (0.72) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL20550753 0.80 MAPK14 (0.91) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL6876676 0.80 MAPK14 (0.70) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL7952440 0.80 MAPK14 (1.00) MAPK14CSNK1DMAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102686580-B imidazole derivatives as casein kinase inhibitors PFIZER 2014-09-10 CN disclosed
EP-2493876-B1 IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS PFIZER (US) 2014-02-12 EP disclosed
EP-2493876-B1 IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS PFIZER (US) 2014-02-12 EP disclosed
US-8518944-B2 Compounds as casein kinase inhibitors PFIZER INC. (US) 2013-08-27 US disclosed
US-8518944-B2 Compounds as casein kinase inhibitors PFIZER INC. (US) 2013-08-27 US disclosed
US-8518944-B2 Compounds as casein kinase inhibitors PFIZER INC. (US) 2013-08-27 US disclosed
CN-102686580-A Imidazole derivatives as casein kinase inhibitors PFIZER 2012-09-19 CN disclosed
EP-2493876-A1 IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS Pfizer Inc. (US) 2012-09-05 EP disclosed
WO-2011051858-A1 IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS PFIZER INC. (US) 2011-05-05 WO disclosed
WO-2011051858-A1 IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS PFIZER INC. (US) 2011-05-05 WO disclosed
US-20110098272-A1 Novel Compounds As Casein Kinase Inhibitors PFIZER INC 2011-04-28 US disclosed
US-20110098272-A1 Novel Compounds As Casein Kinase Inhibitors PFIZER INC 2011-04-28 US disclosed
US-20110098272-A1 Novel Compounds As Casein Kinase Inhibitors PFIZER INC 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098272-A1 Novel Compounds As Casein Kinase Inhibitors CSNK1A1, CSNK1A1L, CSNK1G1 MAPK14 169/4885TGFBR1 3920/4885CSNK1D 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.